Amedeo Smart

Free Medical Literature Service

 

Amedeo

Biliary Tract Diseases
  Free Subscription

Articles published in
Hepatology
    October 2025
  1. HORST LJ, Kempski J, Walmsley M, Huber S, et al
    PSC and colitis: A complex relationship.
    Hepatology. 2025;82:960-984.
    >> Share

    September 2025
  2. TESINI G, Ibrahim H, Rimassa L, Braconi C, et al
    Evolving Precision: Updates in Targeted Therapy for Cholangiocarcinoma.
    Hepatology. 2025 Sep 22. doi: 10.1097/HEP.0000000000001541.
    >> Share

  3. SIMBRUNNER B, Paternostro R, Reiberger T, Trauner M, et al
    Bile acid signaling in MASLD: from pathogenesis to therapeutic applications.
    Hepatology. 2025 Sep 19. doi: 10.1097/HEP.0000000000001539.
    >> Share

  4. DONG Y, Li Z, Gores GJ, Heimbach JK, et al
    Reply: Re-examining neoadjuvant chemoradiation plus transplantation versus liver resection for de novo perihilar cholangiocarcinoma.
    Hepatology. 2025 Sep 10. doi: 10.1097/HEP.0000000000001521.
    >> Share

  5. LI Y, Fan X, Xu X
    Letter to the editor: Re-examining neoadjuvant chemoradiation plus transplantation versus liver resection for de novo perihilar cholangiocarcinoma.
    Hepatology. 2025 Sep 10. doi: 10.1097/HEP.0000000000001519.
    >> Share

  6. WILECHANSKY RM
    Surging sludge: Intrahepatic cholangiocarcinoma mortality on the rise worldwide.
    Hepatology. 2025;82:543-544.
    >> Share

    August 2025
  7. DING J, She HY, Cheng Y, Sun HY, et al
    A novel mechanism involving USP53-regulated BSEP trafficking underlies low-GGT intrahepatic cholestasis.
    Hepatology. 2025 Aug 19. doi: 10.1097/HEP.0000000000001501.
    >> Share

  8. ZENG Q, Xie D, Zhou Q, Qian B, et al
    Letter to the Editor: The treatment options for de novo perihilar cholangiocarcinoma require more details.
    Hepatology. 2025 Aug 13. doi: 10.1097/HEP.0000000000001496.
    >> Share

  9. DONG Y, Li Z, Gores GJ, Heimbach JK, et al
    Reply: The treatment options for de novo perihilar cholangiocarcinoma require more details.
    Hepatology. 2025 Aug 13. doi: 10.1097/HEP.0000000000001497.
    >> Share

  10. ZHANG D, Yang Y, Lu Z
    Letter to the Editor: Biliary tract cancer subtype heterogeneity: An overlooked key analytic dimension.
    Hepatology. 2025 Aug 12. doi: 10.1097/HEP.0000000000001490.
    >> Share

    July 2025
  11. FAN G, Han X, Shi Y
    Reply: Reevaluating PCA and SCTransform usage in single-cell intrahepatic cholangiocarcinoma analysis.
    Hepatology. 2025 Jul 30. doi: 10.1097/HEP.0000000000001480.
    >> Share

  12. TAKEFUJI Y
    Letter to the editor: Reevaluating PCA and SCTransform usage in single-cell intrahepatic cholangiocarcinoma analysis.
    Hepatology. 2025 Jul 29. doi: 10.1097/HEP.0000000000001479.
    >> Share

  13. APODAKA-BIGURI M, Simao AL, Gonzalez-Romero F, Mestre D, et al
    E2F2 transcription factor promotes a cholestatic MASH phenotype by regulating hepatobiliary metabolism through miR-34a-5p.
    Hepatology. 2025 Jul 28. doi: 10.1097/HEP.0000000000001461.
    >> Share

  14. ABRUZZESE GA, Martinez-Chantar ML
    Minor players, major signals: Unveiling the systemic and gut-localized impact of microbial amidated bile acids in hepatopancreatobiliary disease.
    Hepatology. 2025 Jul 21. doi: 10.1097/HEP.0000000000001473.
    >> Share

  15. NOMDEN M, Kuipers F, Lexmond WS, Gu T, et al
    Pretreatment serum bile acid composition and predictability of subsequent response to odevixibat in patients with bile salt export pump (BSEP) deficiency.
    Hepatology. 2025 Jul 11. doi: 10.1097/HEP.0000000000001430.
    >> Share

  16. DONG Y, Li Z, Podrascanin V, Eaton JE, et al
    Liver resection with and without vascular resection versus transplantation for de novo perihilar cholangiocarcinoma.
    Hepatology. 2025 Jul 4. doi: 10.1097/HEP.0000000000001449.
    >> Share

  17. GUO Y, Zhang Q, Li B, Dai W, et al
    Biliary YB-1/GLI2 axis facilitates ductular reaction and promotes hepatic stellate cell activation via SPP1/Integrin alphavbeta1 signaling during liver fibrogenesis.
    Hepatology. 2025 Jul 4. doi: 10.1097/HEP.0000000000001458.
    >> Share

  18. KENNEDY L, Hargrove L, Demieville J, Karstens W, et al
    Retraction: Blocking H1/H2 histamine receptors inhibits damage/fibrosis in Mdr2-/- mice and human cholangiocarcinoma tumorigenesis.
    Hepatology. 2025 Jul 2. doi: 10.1097/HEP.0000000000001403.
    >> Share

  19. TRAUNER M, Karpen SJ, Dawson PA
    Benefits and challenges to therapeutic targeting of bile acid circulation in cholestatic liver disease.
    Hepatology. 2025 Jul 2. doi: 10.1097/HEP.0000000000001438.
    >> Share

  20. MANCINELLI R, Franchitto A, Glaser S, Meng F, et al
    Retraction: GABA induces the differentiation of small into large cholangiocytes by activation of Ca2+/CaMK I-dependent adenylyl cyclase 8.
    Hepatology. 2025;82:E22.
    >> Share

  21. LI B, Ilyas SI
    The dynamic duo: How tumor-associated macrophages and tumor cells team up in cholangiocarcinoma.
    Hepatology. 2025;82:1-2.
    >> Share

  22. HAMMONS J, Warren EK, Wittling MC, Bennett FJ, et al
    Tumor site influences efficacy of MEKi and immunotherapy combinations in pre-clinical model of cholangiocarcinoma.
    Hepatology. 2025 Jul 1. doi: 10.1097/HEP.0000000000001439.
    >> Share

    June 2025
  23. CHUNG BK, Jordens MS, Ogaard J, Reims HM, et al
    Multimodal transcriptomics identifies metallothionein as a novel pathway in primary sclerosing cholangitis.
    Hepatology. 2025 Jun 25. doi: 10.1097/HEP.0000000000001432.
    >> Share

  24. TEMPRANO AG, Romero MR, Ghallab A, Llera L, et al
    Gut-to-Bile transfer of microbially amidated minor bile acids in patients with hepatopancreatobiliary disorders.
    Hepatology. 2025 Jun 23. doi: 10.1097/HEP.0000000000001441.
    >> Share

  25. CARPINO G, Overi D, Macias RI, Cardinale V, et al
    Refinement of histologic subtypes and identification of biomarkers linked to unfavorable prognosis in cholangiocarcinoma: The ENSCCA registries' framework for digital twin advancement.
    Hepatology. 2025 Jun 16. doi: 10.1097/HEP.0000000000001425.
    >> Share

  26. LI F, Li Y, Wang L, Xu L, et al
    Tumor microenvironment heterogeneity and progression mechanisms in intrahepatic cholangiocarcinoma: A study based on single-cell and spatial transcriptomic sequencing.
    Hepatology. 2025 Jun 9. doi: 10.1097/HEP.0000000000001423.
    >> Share

  27. BIAN Q, Wang S, Song Z, Liu F, et al
    Arid1a deficiency promotes hepatocyte hyperpolyploidy and drives intrahepatic cholangiocarcinoma in mice.
    Hepatology. 2025 Jun 9. doi: 10.1097/HEP.0000000000001422.
    >> Share

  28. YAN B, Lai W, Wang Z
    Letter to the editor: Mitigating missing data bias and confounding on large-scale cohort studies of metabolic syndrome-cholangiocarcinoma associations.
    Hepatology. 2025 Jun 3. doi: 10.1097/HEP.0000000000001418.
    >> Share

    May 2025
  29. O'ROURKE CJ, Andersen JB
    Intrahepatic Cholangiocarcinoma PANoptosidy.
    Hepatology. 2025 May 8. doi: 10.1097/HEP.0000000000001398.
    >> Share

    April 2025
  30. LEE MH
    Reply: Oversights in Stratification and Viral Screening- A Critical Appraisal of a MetS-Cholangiocarcinoma Cohort.
    Hepatology. 2025 Apr 29. doi: 10.1097/HEP.0000000000001370.
    >> Share

  31. HUANG J
    Letter to the editor: Oversights in stratification and viral screening- A critical appraisal of a MetS-cholangiocarcinoma cohort.
    Hepatology. 2025 Apr 29. doi: 10.1097/HEP.0000000000001369.
    >> Share

  32. HOLMER M, Ingre M, Farkkila M, Ponsioen C, et al
    Cirrhosis and age are key determinants of HCC risk in individuals with primary sclerosing cholangitis: A multicenter longitudinal cohort study.
    Hepatology. 2025 Apr 16. doi: 10.1097/HEP.0000000000001351.
    >> Share

  33. YU Y, You Y, Duan Y, Kang M, et al
    Multiomics approaches for identifying the PANoptosis signature and prognostic model via a multimachine-learning computational framework for intrahepatic cholangiocarcinoma.
    Hepatology. 2025 Apr 15. doi: 10.1097/HEP.0000000000001352.
    >> Share

  34. LUNDBERG BAVE A, von Seth E, Ingre M, Nordenvall C, et al
    Reply: Primary sclerosing cholangitis and autoimmune hepatitis - distinct or common autoimmune penetrance?
    Hepatology. 2025 Apr 11. doi: 10.1097/HEP.0000000000001326.
    >> Share

  35. YANG LX, Gao Q, Shi JY, Wang ZC, et al
    Erratum: Mitogen-activated protein kinase kinase kinase 4 deficiency in intrahepatic cholangiocarcinoma leads to invasive growth and epithelial-mesenchymal transition.
    Hepatology. 2025 Apr 7. doi: 10.1097/HEP.0000000000001274.
    >> Share

  36. SAMPLE JW
    A Niche Discovery: Spatial Mapping of Therapeutic Targets in Biliary Atresia.
    Hepatology. 2025;81:1109-1110.
    >> Share

  37. MOL B, Werner E, Culver EL, van der Meer AJ, et al
    Epidemiological and economical burden of cholestatic liver disease.
    Hepatology. 2025 Apr 1. doi: 10.1097/HEP.0000000000001341.
    >> Share

    March 2025
  38. GRONBAEK L, Vilstrup H, Jepsen P
    Letter to the Editor: Primary sclerosing cholangitis and autoimmune hepatitis - distinct or common autoimmune penetrance?
    Hepatology. 2025 Mar 25. doi: 10.1097/HEP.0000000000001325.
    >> Share

  39. LEVY C, Bowlus CL
    Erratum: Primary biliary cholangitis: Personalizing second-line therapies.
    Hepatology. 2025 Mar 24. doi: 10.1097/HEP.0000000000001275.
    >> Share

  40. MACIAS RIR, Roessler S, Verstegen MMA
    Deciphering the spatial tumor microenvironment in intrahepatic cholangiocarcinoma.
    Hepatology. 2025 Mar 24. doi: 10.1097/HEP.0000000000001322.
    >> Share

  41. CHEN TI, Chen MH, Yin SC, Lin CJ, et al
    Associations between metabolic syndrome and cholangiocarcinoma risk: A large-scale population-based cohort study.
    Hepatology. 2025 Mar 21. doi: 10.1097/HEP.0000000000001312.
    >> Share

  42. SINGH Y, Eaton JE, Venkatesh SK, Welle CL, et al
    Deep learning analysis of magnetic resonance imaging accurately detects early-stage perihilar cholangiocarcinoma in patients with primary sclerosing cholangitis.
    Hepatology. 2025 Mar 20. doi: 10.1097/HEP.0000000000001314.
    >> Share

  43. GORES GJ, Malhi H
    The dynamic landscape of cholestatic liver disease.
    Hepatology. 2025 Mar 7. doi: 10.1097/HEP.0000000000001298.
    >> Share

    February 2025
  44. HONG L, Mei J, Sun X, Wu Y, et al
    Spatial single-cell proteomics landscape decodes the tumor microenvironmental ecosystem of intrahepatic cholangiocarcinoma.
    Hepatology. 2025 Feb 25. doi: 10.1097/HEP.0000000000001283.
    >> Share

  45. CANCADO GGL, Deeb M, Gulamhusein AF
    Liver transplantation for cholestatic liver diseases: Timing & disease recurrence.
    Hepatology. 2025 Feb 17. doi: 10.1097/HEP.0000000000001268.
    >> Share

  46. OLAIZOLA P, Olaizola I, Fernandez de Ara M, Lapitz A, et al
    Targeting protein hyperSUMOylation halts cholangiocarcinoma progression by impairing cancer cell viability and tumor-stroma crosstalk.
    Hepatology. 2025 Feb 11. doi: 10.1097/HEP.0000000000001259.
    >> Share

  47. YU M, Sample JW, Yan IK, Takaichi S, et al
    Aptamer-directed, nanovesicle-mediated targeting of undruggable molecules in preclinical cholangiocarcinoma models.
    Hepatology. 2025 Feb 10. doi: 10.1097/HEP.0000000000001256.
    >> Share

  48. LI B
    BileMet: A new frontier in distinguishing malignant from benign biliary conditions.
    Hepatology. 2025;81:383-384.
    >> Share

    January 2025
  49. LI B, Ilyas SI
    Unveiling the immune landscape of IDH1-mutant cholangiocarcinoma: Pathways to new therapies.
    Hepatology. 2025 Jan 21. doi: 10.1097/HEP.0000000000001241.
    >> Share

  50. RONCA V, Davies SP, Oo YH, Lleo A, et al
    The immunological landscape of primary biliary cholangitis: Mechanisms and therapeutic prospects.
    Hepatology. 2025 Jan 3. doi: 10.1097/HEP.0000000000001225.
    >> Share

  51. IDALSOAGA F, Arab JP
    Unraveling bile acid dynamics in severe obesity.
    Hepatology. 2025;81:1-2.
    >> Share

    December 2024
  52. BITTERMANN T, Schaubel DE
    Obeticholic acid as second-line therapy for primary biliary cholangitis: Does target trial emulation solve the issue?
    Hepatology. 2024 Dec 20. doi: 10.1097/HEP.0000000000001198.
    >> Share

  53. THI VU Q, Nishimura Y, Harada K, Ito H, et al
    International trends in biliary tract cancer-related mortality, 2000-2022: An observational study of the World Health Organization mortality database.
    Hepatology. 2024 Dec 19. doi: 10.1097/HEP.0000000000001200.
    >> Share

  54. LUO Y, Fraser L, Jezykowski J, Gupta NA, et al
    Interleukin 8-CXCR2 mediated neutrophil extracellular trap (NET) formation in biliary atresia associated with NET-Induced stellate cell activation.
    Hepatology. 2024 Dec 18. doi: 10.1097/HEP.0000000000001195.
    >> Share

  55. CONDE DE LA ROSA L, Fabrega L, Torres S, Nunez S, et al
    Stard1 promotes cholestatic liver injury and disease progression by sensitizing to bile acid hepatotoxicity.
    Hepatology. 2024 Dec 9. doi: 10.1097/HEP.0000000000001184.
    >> Share

  56. ZABRANSKY DJ, Kartalia E, Lee JW, Leatherman JM, et al
    Tumor-derived CCL2 drives tumor growth and immunosuppression in IDH1-mutant cholangiocarcinoma.
    Hepatology. 2024 Dec 3. doi: 10.1097/HEP.0000000000001185.
    >> Share

  57. BROOKHART MA, Mayne TJ, Coombs C, Breskin A, et al
    Hepatic real-world outcomes with obeticholic acid in primary biliary cholangitis (HEROES): A trial emulation study design.
    Hepatology. 2024 Dec 2. doi: 10.1097/HEP.0000000000001174.
    >> Share

    November 2024
  58. KARLSEN TH, Kaasen Jorgensen K, Bergquist A
    Medical treatment of primary sclerosing cholangitis: What have we learned and where are we going?
    Hepatology. 2024 Nov 22. doi: 10.1097/HEP.0000000000001172.
    >> Share

  59. LEVY C, Bowlus CL
    Primary Biliary Cholangitis: personalizing second-line therapies.
    Hepatology. 2024 Nov 12. doi: 10.1097/HEP.0000000000001166.
    >> Share

    October 2024
  60. FAN G, Tao C, Li L, Xie T, et al
    The co-location of MARCO+ tumor-associated macrophages and CTSE+ tumor cells determined the poor prognosis in intrahepatic cholangiocarcinoma.
    Hepatology. 2024 Oct 29. doi: 10.1097/HEP.0000000000001138.
    >> Share

  61. CIRIA R, Ivanics T, Aliseda D, Claasen M, et al
    Liver transplantation for primary and secondary liver tumours. patient-level meta-analyses compared to unos conventional indications.
    Hepatology. 2024 Oct 28. doi: 10.1097/HEP.0000000000001129.
    >> Share

  62. SCHNEIDER KM, Kummen M, Trivedi PJ, Hov JR, et al
    Role of microbiome in autoimmune liver diseases.
    Hepatology. 2024;80:965-987.
    >> Share

    September 2024
  63. JALAN-SAKRIKAR N, Guicciardi ME, O'Hara SP, Azad A, et al
    Central role for cholangiocyte pathobiology in cholestatic liver diseases.
    Hepatology. 2024 Sep 9. doi: 10.1097/HEP.0000000000001093.
    >> Share

  64. CORNILLET M, Geanon D, Bergquist A, Bjorkstrom NK, et al
    Immunobiology of primary sclerosing cholangitis.
    Hepatology. 2024 Sep 2. doi: 10.1097/HEP.0000000000001080.
    >> Share

    August 2024
  65. PANT K, Richard S, Peixoto E, Baral S, et al
    Cholangiocyte ciliary defects induce sustained epidermal growth factor receptor signaling.
    Hepatology. 2024 Aug 23. doi: 10.1097/HEP.0000000000001055.
    >> Share

  66. XIAO MH, Ma D, Wu S, Huang Z, et al
    Integrative single-cell and spatial transcriptomic analyses identify a pathogenic cholangiocyte niche and TNFRSF12A as therapeutic target for biliary atresia.
    Hepatology. 2024 Aug 23. doi: 10.1097/HEP.0000000000001064.
    >> Share

  67. BJORNSSON ES, Devarbhavi HC
    Drug induced cholestatic liver diseases.
    Hepatology. 2024 Aug 8. doi: 10.1097/HEP.0000000000001052.
    >> Share

  68. BANALES JM, Lapitz A, Fabris L
    Comparative performance of methylation DNA markers, brushing cytology, and FISH in diagnosing malignant biliary strictures.
    Hepatology. 2024 Aug 8. doi: 10.1097/HEP.0000000000001050.
    >> Share

    July 2024
  69. ZHANG X, Liu H, Cai P, Huang Z, et al
    Mdka produced by the activated HSCs drives bipotential progenitor cell redifferentiation during zebrafish biliary-mediated liver regeneration.
    Hepatology. 2024 Jul 30. doi: 10.1097/HEP.0000000000001031.
    >> Share

  70. SUTTON H, Sokol RJ, Kamath BM
    IBAT inhibitors in pediatric cholestatic liver diseases: Transformation on the horizon?
    Hepatology. 2024 Jul 25. doi: 10.1097/HEP.0000000000001032.
    >> Share

  71. ZHUANG Y, Ortega-Ribera M, Szabo G
    Reply to: Exercise greater caution in bile acid research.
    Hepatology. 2024 Jul 17. doi: 10.1097/HEP.0000000000001017.
    >> Share

  72. YI C, Chen L, Tao B, Wang X, et al
    Letter to the Editor: Exercise greater caution in bile acid research.
    Hepatology. 2024 Jul 17. doi: 10.1097/HEP.0000000000001013.
    >> Share

  73. ZHANG L, Xie P, Li M, Zhang X, et al
    Hepatic GDP-fucose transporter SLC35C1 attenuates cholestatic liver injury and inflammation by inducing CEACAM1 N153 fucosylation.
    Hepatology. 2024 Jul 10. doi: 10.1097/HEP.0000000000001003.
    >> Share

    June 2024
  74. ZHU M, Qu M, Lv S, Pan F, et al
    Letter to the Editor: Enhancing the rigor and impact of cholangiocarcinoma research: Addressing key concerns in the PTPN9-FGFR2 interaction study.
    Hepatology. 2024 Jun 24. doi: 10.1097/HEP.0000000000000932.
    >> Share

  75. COOLEY MA, Schneider AR, Barr Fritcher EG, Milosevic D, et al
    Utility of methylated DNA markers for the diagnosis of malignant biliary strictures.
    Hepatology. 2024 Jun 21. doi: 10.1097/HEP.0000000000000970.
    >> Share

  76. OH DY, Ikeda M, Lee CK, Rojas C, et al
    Bintrafusp alfa and chemotherapy as first-line treatment in biliary tract cancer: A randomized phase 2/3 trial.
    Hepatology. 2024 Jun 14. doi: 10.1097/HEP.0000000000000965.
    >> Share

  77. YANG S, Fu J, Qin W, Wang R, et al
    Bile metabolic fingerprints distinguish biliary tract cancer from benign biliary diseases.
    Hepatology. 2024 Jun 11. doi: 10.1097/HEP.0000000000000957.
    >> Share

  78. HUANG YH, Loftfield E, Argirion I, Adami HO, et al
    Association of tea and coffee consumption and biliary tract cancer risk: The Biliary Tract Cancers Pooling Project.
    Hepatology. 2024;79:1324-1336.
    >> Share

  79. HANSEN BE, Vandriel SM, Vig P, Garner W, et al
    Event-free survival of maralixibat-treated patients with Alagille syndrome compared to a real-world cohort from GALA.
    Hepatology. 2024;79:1279-1292.
    >> Share

    May 2024
  80. AYDIN O, Wahlstrom A, de Jonge PA, Meijnikman AS, et al
    An integrated analysis of bile acid metabolism in humans with severe obesity.
    Hepatology. 2024 May 28. doi: 10.1097/HEP.0000000000000938.
    >> Share

  81. KELLERMAYER R, Carbone M, Horvath TD, Szigeti RG, et al
    Identifying a therapeutic window of opportunity for people living with primary sclerosing cholangitis: Embryology and the overlap of inflammatory bowel disease with immune mediated liver injury.
    Hepatology. 2024 May 14. doi: 10.1097/HEP.0000000000000926.
    >> Share

    April 2024
  82. HITOMI Y, Ueno K, Aiba Y, Nishida N, et al
    A genome-wide association study identified PTPN2 as a population-specific susceptibility gene locus for primary biliary cholangitis.
    Hepatology. 2024 Apr 23. doi: 10.1097/HEP.0000000000000894.
    >> Share

    March 2024
  83. JONES DE, Beuers U, Bonder A, Carbone M, et al
    Primary biliary cholangitis drug evaluation and regulatory approval: Where do we go from here?
    Hepatology. 2024 Mar 22. doi: 10.1097/HEP.0000000000000864.
    >> Share

  84. LAL BB, Alam S, Sibal A, Kumar K, et al
    Genotype correlates with clinical course and outcome of children with tight junction protein 2 (TJP2) deficiency-related cholestasis.
    Hepatology. 2024 Mar 6. doi: 10.1097/HEP.0000000000000828.
    >> Share

  85. AMPUERO J, Lucena A, Berenguer M, Hernandez-Guerra M, et al
    Predictive factors for decompensating events in cirrhotic patients with primary biliary cholangitis under different lines of therapy.
    Hepatology. 2024 Mar 6. doi: 10.1097/HEP.0000000000000826.
    >> Share

  86. PANDURANGI S, Mourya R, Nalluri S, Fei L, et al
    Diagnostic accuracy of serum matrix metalloproteinase-7 as a biomarker of biliary atresia in a large North American cohort.
    Hepatology. 2024 Mar 6. doi: 10.1097/HEP.0000000000000827.
    >> Share

  87. ZHUANG Y, Szabo G
    Reply to: How does bile acid-induced IRF3 phosphorylation mediate cholestatic liver and kidney injury? more need to be known.
    Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000816.
    >> Share

  88. KELLERER M, Javed S, Casar C, Will N, et al
    Antagonistic effects of the cytotoxic molecules granzyme B and TRAIL in the immunopathogenesis of sclerosing cholangitis.
    Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000830.
    >> Share

  89. JIANG L, Yang Z
    Letter to the Editor: How does bile acid-induced IRF3 phosphorylation mediate cholestatic liver and kidney injury? ---more need to be known.
    Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000813.
    >> Share

  90. LUNDBERG BAVE A, von Seth E, Ingre M, Nordenvall C, et al
    Autoimmune diseases in primary sclerosing cholangitis and their first-degree relatives.
    Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000823.
    >> Share

    February 2024
  91. ZHANG H, Zhu K, Zhang R, Guo Y, et al
    Oleic acid-PPARgamma-FABP4 loop fuels cholangiocarcinoma colonization in lymph node metastases microenvironment.
    Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000784.
    >> Share

    January 2024
  92. WILBUR HC, Soares HP, Azad NS
    Neoadjuvant and adjuvant therapy for biliary tract cancer: Advances and limitations.
    Hepatology. 2024 Jan 24. doi: 10.1097/HEP.0000000000000760.
    >> Share

  93. BARGELLINI I, Rimassa L, Masi G
    SIRT and chemotherapy in unresectable iCCA: Ready to take off.
    Hepatology. 2024;79:9-11.
    >> Share

  94. CORPECHOT C, Lemoinne S, Soret PA, Hansen B, et al
    Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?
    Hepatology. 2024;79:39-48.
    >> Share

    December 2023
  95. CORPECHOT C, Lemoinne S, Soret PA, Chazouilleres O, et al
    Reply: Improving access to transient elastography data for Real-World Prognostic Applications in primary biliary cholangitis.
    Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000746.
    >> Share

  96. WIEGAND J, Franke A, Stein K, Trautwein C, et al
    Letter to the Editor: Improving access to transient elastography data for real-world prognostic applications in primary biliary cholangitis.
    Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000744.
    >> Share

  97. KREMER AE, Mayo MJ, Hirschfield GM, Levy C, et al
    Seladelpar treatment reduces interleukin-31 and pruritus in patients with primary biliary cholangitis.
    Hepatology. 2023 Dec 20. doi: 10.1097/HEP.0000000000000728.
    >> Share

    November 2023
  98. GHOSH S, Devereaux MW, Liu C, Sokol RJ, et al
    LRH-1 agonist DLPC through STAT6 promotes macrophage polarization and prevents parenteral nutrition associated cholestasis in mice.
    Hepatology. 2023 Nov 17. doi: 10.1097/HEP.0000000000000690.
    >> Share

  99. GEHL V, O'Rourke CJ, Andersen JB
    Immunogenomics of cholangiocarcinoma.
    Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000688.
    >> Share

  100. HE S, Peng Y, Wei Q
    Letter to the Editor: Lack of complete biochemical response in autoimmune hepatitis leads to adverse outcome: First report of the IAIHG retrospective registry.
    Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000685.
    >> Share

  101. SLOOTER CD, van den Brand FF, Lleo A, Liberal R, et al
    Reply - Lack of complete biochemical response in autoimmune hepatitis leads to adverse outcome: first report of the IAIHG retrospective registry.
    Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000689.
    >> Share

  102. LIU ZP, Sun XH, Yu C, Yin XY, et al
    Letter to the Editor: How to define the futile outcome in patients undergoing surgery for perihilar cholangiocarcinoma?
    Hepatology. 2023 Nov 7. doi: 10.1097/HEP.0000000000000651.
    >> Share

  103. NIKNEJAD N, Fox D, Burwinkel JL, Zarrin-Khameh N, et al
    ASO silencing of a glycosyltransferase, Poglut1 , improves the liver phenotypes in mouse models of Alagille syndrome.
    Hepatology. 2023;78:1337-1351.
    >> Share

  104. YANG F, Hilakivi-Clarke L, Shaha A, Wang Y, et al
    Metabolic reprogramming and its clinical implication for liver cancer.
    Hepatology. 2023;78:1602-1624.
    >> Share

    October 2023
  105. RATTI F, Marino R, Groot Koerkamp B, Aldrighetti L, et al
    Reply: "How to define the futile outcome in patients undergoing surgery for perihilar cholangiocarcinoma".
    Hepatology. 2023 Oct 31. doi: 10.1097/HEP.0000000000000659.
    >> Share

  106. SELLERS ZM, Assis DN, Paranjape SM, Sathe M, et al
    Cystic fibrosis screening, evaluation and management of hepatobiliary disease consensus recommendations.
    Hepatology. 2023 Oct 26. doi: 10.1097/HEP.0000000000000646.
    >> Share

  107. HU YF, Ma WJ, Jin YW, Li FY, et al
    Adjuvant chemotherapy for resected biliary tract cancers: A fluorouracil-based scheme beats out a gemcitabine-based scheme for the win.
    Hepatology. 2023 Oct 23. doi: 10.1097/HEP.0000000000000634.
    >> Share


  108. Erratum: Modulation of the tryptophan hydroxylase 1/monoamine oxidase-A/5-hydroxytryptamine/5-hydroxytryptamine receptor 2A/2B/2C axis regulates biliary proliferation and liver fibrosis during cholestasis.
    Hepatology. 2023;78:E86.
    >> Share

    September 2023
  109. GELLERT-KRISTENSEN H, Bojesen SE, Tybjaerg-Hansen A, Stender S, et al
    Telomere length and risk of cirrhosis, hepatocellular carcinoma, and cholangiocarcinoma in 63,272 individuals from the general population.
    Hepatology. 2023 Sep 19. doi: 10.1097/HEP.0000000000000608.
    >> Share

  110. ZHUANG Y, Ortega-Ribera M, Thevkar Nagesh P, Joshi R, et al
    Bile acid-induced IRF3 phosphorylation mediates cell death, inflammatory responses and fibrosis in cholestasis-induced liver and kidney injury via regulation of ZBP1.
    Hepatology. 2023 Sep 19. doi: 10.1097/HEP.0000000000000611.
    >> Share

  111. SLOOTER CD, van den Brand FF, Lleo A, Colapietro F, et al
    Lack of complete biochemical response in autoimmune hepatitis leads to adverse outcome: first report of the IAIHG retrospective registry.
    Hepatology. 2023 Sep 4. doi: 10.1097/HEP.0000000000000589.
    >> Share

    August 2023
  112. PEISELER M, Tacke F
    Bile duct-associated macrophages enter the spotlight in inflammatory cholestatic liver disease.
    Hepatology. 2023 Aug 22. doi: 10.1097/HEP.0000000000000576.
    >> Share

  113. RATTI F, Marino R, Olthof PB, Pratschke J, et al
    Predicting futility of upfront surgery in perihilar cholangiocarcinoma: Machine learning analytics model to optimize treatment allocation.
    Hepatology. 2023 Aug 3. doi: 10.1097/HEP.0000000000000554.
    >> Share

  114. DE MUYNCK K, Heyerick L, De Ponti FF, Vanderborght B, et al
    Osteopontin characterizes bile duct associated macrophages and correlates with liver fibrosis severity in primary sclerosing cholangitis.
    Hepatology. 2023 Aug 2. doi: 10.1097/HEP.0000000000000557.
    >> Share

  115. BOWLUS CL, Levy C
    Optimizing treatment of primary biliary cholangitis: Is good, good enough?
    Hepatology. 2023 Aug 2. doi: 10.1097/HEP.0000000000000556.
    >> Share

    July 2023
  116. ZHAO L, Liu J, Li K, Zhang C, et al
    PTPN9 dephosphorylates FGFR2pY656/657 via interaction with ACAP1 and ameliorates pemigatinib effect in cholangiocarcinoma.
    Hepatology. 2023 Jul 27. doi: 10.1097/HEP.0000000000000552.
    >> Share

  117. LI Y, Li B, Xiao X, Qian Q, et al
    Itaconate inhibits CD103+ TRM cells and alleviates hepatobiliary injury in mouse models of primary sclerosing cholangitis.
    Hepatology. 2023 Jul 26. doi: 10.1097/HEP.0000000000000549.
    >> Share

  118. EDELINE J, Bridgewater J, Campillo-Gimenez B, Neveu E, et al
    Chemotherapy with or without selective internal radiation therapy for intrahepatic cholangiocarcinoma: Data from clinical trials.
    Hepatology. 2023 Jul 25. doi: 10.1097/HEP.0000000000000544.
    >> Share


  119. Retraction: Altered store operated calcium entry increases cyclic 3',5'-adenosine monophosphate production and extracellular signal-regulated kinases 1 and 2 phosphorylation in polycystin-2-defective cholangiocytes.
    Hepatology. 2023 Jul 21. doi: 10.1097/HEP.0000000000000484.
    >> Share

  120. JEONG H, Yoo C
    Reply: Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: The STAMP randomized trial - author's reply.
    Hepatology. 2023 Jul 17. doi: 10.1097/HEP.0000000000000535.
    >> Share

  121. HU YF, Gu HF, Jin YW, Li FY, et al
    Letter to the Editor: Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: The STAMP randomized trial.
    Hepatology. 2023 Jul 17. doi: 10.1097/HEP.0000000000000532.
    >> Share

    June 2023
  122. SOKOL RJ, Gonzales EM, Kamath BM, Baker A, et al
    Predictors of 6-year event-free survival in alagille syndrome patients treated with maralixibat, an ileal bile acid transporter inhibitor.
    Hepatology. 2023 Jun 7. doi: 10.1097/HEP.0000000000000502.
    >> Share

  123. EKSER B, Sucu S, Mihaylov P, Emamaullee JA, et al
    Letter to the Editor mucosal gut microbiota in primary sclerosing cholangitis before and after liver transplantation: Are there other challenges?
    Hepatology. 2023 Jun 5. doi: 10.1097/HEP.0000000000000503.
    >> Share

    May 2023
  124. NEJAK-BOWEN K, Monga SP
    Wnt-beta-catenin in hepatobiliary homeostasis, injury, and repair.
    Hepatology. 2023 May 30. doi: 10.1097/HEP.0000000000000495.
    >> Share


  125. Erratum: IL-6-induced cGGNBP2 encodes a protein to promote cell growth and metastasis in intrahepatic cholangiocarcinoma.
    Hepatology. 2023 May 15. doi: 10.1097/HEP.0000000000000040.
    >> Share

  126. SHU L, Li X, Liu Z, Li K, et al
    Bile exosomal miR-182/183-5p increases cholangiocarcinoma stemness and progression by targeting HPGD and increasing PGE2 generation.
    Hepatology. 2023 May 5. doi: 10.1097/HEP.0000000000000437.
    >> Share

  127. JEONG H, Kim KP, Jeong JH, Hwang DW, et al
    Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: the STAMP randomized trial.
    Hepatology. 2023;77:1540-1549.
    >> Share

  128. FORMAN LM, Sapisochin G, Assis DN, Arrive L, et al
    Reply: Living donor liver transplantation for people with PSC.
    Hepatology. 2023;77:E97-E98.
    >> Share

    April 2023
  129. MACKOWIAK B, Gao B
    Activation of cholangiocyte mTORC1 drives alcohol-induced ductular reaction.
    Hepatology. 2023 Apr 21. doi: 10.1097/HEP.0000000000000416.
    >> Share

  130. RUSSI AE, Shivakumar P, Luo Z, Bezerra J, et al
    Plasticity between ILC2 subsets and amphiregulin expression regulate epithelial repair in biliary atresia.
    Hepatology. 2023 Apr 21. doi: 10.1097/HEP.0000000000000418.
    >> Share

  131. DANIEL N, Genua F, Jenab M, Mayen AL, et al
    The role of the gut microbiome in the development of hepatobiliary cancers.
    Hepatology. 2023 Apr 15. doi: 10.1097/HEP.0000000000000406.
    >> Share

  132. HARTL L, Reiberger T, Trauner M
    Reply: progressive cholestasis and associated sclerosing cholangitis are complications of COVID-19 in patients with chronic liver disease.
    Hepatology. 2023 Apr 11. doi: 10.1097/HEP.0000000000000399.
    >> Share

  133. UMAR S, Nadeem A, Nadeem M
    Letter to the editor: progressive cholestasis and associated sclerosing cholangitis are complications of COVID-19 in patients with chronic liver disease.
    Hepatology. 2023 Apr 11. doi: 10.1097/HEP.0000000000000398.
    >> Share

  134. HIRSCHFIELD GM, Shiffman ML, Gulamhusein A, Kowdley KV, et al
    Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study.
    Hepatology. 2023 Apr 6. doi: 10.1097/HEP.0000000000000395.
    >> Share

  135. YOO C, Javle MM, Verdaguer Mata H, de Braud F, et al
    Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally advanced/metastatic biliary tract cancers.
    Hepatology. 2023 Apr 3. doi: 10.1097/HEP.0000000000000365.
    >> Share

  136. CABALLERO-CAMINO FJ, Rodrigues PM, Wangsell F, Agirre-Lizaso A, et al
    A3907, a systemic ASBT inhibitor, improves cholestasis in mice by multi-organ activity and shows translational relevance to humans.
    Hepatology. 2023 Apr 3. doi: 10.1097/HEP.0000000000000376.
    >> Share

  137. SINGH SP, Mondia N
    Letter to the Editor: Much more needed in natural history of Alagille syndrome.
    Hepatology. 2023;77:E78.
    >> Share

    January 2023
  138. CANTALLOPS VILA P, Ravichandra A, Agirre Lizaso A, Perugorria MJ, et al
    Heterogeneity, crosstalk and targeting of cancer associated fibroblasts in cholangiocarcinoma.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000206.
    >> Share

  139. HEINEMANN M, Adam R, Karam V, Schramm C, et al
    Letter to the Editor: Living donor liver transplantation for people with PSC.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000208.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016